LL-37: The Human Antimicrobial Peptide

LL-37 is the only cathelicidin antimicrobial peptide produced in humans, making it a uniquely important component of innate immune defense. This 37-amino acid peptide (beginning with two leucine residues, hence "LL") is cleaved from the precursor protein hCAP-18 by proteinase 3 in neutrophils and by kallikreins in epithelial tissues. Beyond direct antimicrobial killing, LL-37 functions as a multifaceted immune signaling molecule with roles in chemotaxis, wound healing, and inflammatory modulation.

Production and Distribution

LL-37 is produced throughout the body as a first-line defense mechanism:

Source	Storage/Release	Trigger
Neutrophils	Specific granules (constitutive)	Degranulation at infection sites
Macrophages	Induced expression	TLR activation, vitamin D signaling
Epithelial cells (skin, airway, gut)	Induced expression	Pathogen contact, injury, vitamin D
Keratinocytes	Induced in wound edges	Injury, UV exposure
Mast cells	Granule release	IgE crosslinking, infection

The Vitamin D Connection

LL-37 expression is directly regulated by vitamin D through the vitamin D receptor (VDR). The gene encoding hCAP-18 (CAMP) contains a vitamin D response element (VDRE) in its promoter region. This explains why vitamin D deficiency is associated with increased infection susceptibility: low vitamin D means low LL-37 production, compromising innate immune defense.

Antimicrobial Mechanism

LL-37 adopts an amphipathic alpha-helical conformation in membrane environments. The cationic face (positive charge from arginine and lysine residues) is attracted to negatively charged bacterial membrane phospholipids, while mammalian cell membranes (enriched in neutral phospholipids and cholesterol) are largely spared.

Membrane Disruption Models

Model	Mechanism	Result
Carpet model	LL-37 accumulates on membrane surface like a carpet	Membrane destabilization at critical concentration
Toroidal pore	LL-37 induces curvature, forming lipid-peptide pores	Ion leakage, membrane depolarization
Detergent-like	At high concentrations, micelle-like membrane solubilization	Complete membrane dissolution

LL-37 shows broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, fungi (Candida species), and enveloped viruses. Resistance development is inherently difficult because bacteria would need to fundamentally restructure their membrane composition.

Immunomodulatory Functions

LL-37's role extends far beyond direct microbial killing:

• Chemotaxis: Recruits neutrophils, monocytes, and T-cells to infection sites via FPR2 receptor activation
• LPS neutralization: Binds and neutralizes bacterial endotoxin (lipopolysaccharide), preventing septic cascade activation
• Wound healing: Promotes keratinocyte migration, angiogenesis, and re-epithelialization through EGFR transactivation
• Dendritic cell modulation: Influences DC maturation and antigen presentation, bridging innate and adaptive immunity
• Biofilm disruption: Prevents bacterial biofilm formation and disrupts established biofilms at sub-bactericidal concentrations

Disease Associations

Condition	LL-37 Status	Clinical Significance
Chronic wounds	Deficient	Impaired antimicrobial defense, delayed healing
Morbus Kostmann	Absent (genetic)	Severe periodontal disease, recurrent infections
Atopic dermatitis	Reduced	Increased susceptibility to skin infections
Psoriasis	Overexpressed	LL-37-self-DNA complexes activate TLR9 autoimmunity
Rosacea	Aberrant processing	Modified LL-37 fragments promote inflammation
Crohn disease	Reduced in colon	Impaired mucosal defense

Comparison to Other Immune Peptides

Peptide	Class	Size	Primary Function
LL-37	Cathelicidin	37 AA	Antimicrobial + immunomodulatory
KPV	α-MSH fragment	3 AA	Anti-inflammatory (NF-κB)
Thymosin Alpha-1	Thymic peptide	28 AA	T-cell maturation
β-Defensin-2	Defensin	41 AA	Antimicrobial (epithelial)

Research Considerations

LL-37 is a relatively large peptide (37 AA, ~4.5 kDa) that can be challenging to synthesize at high purity. Verify via Certificate of Analysis with both HPLC and mass spectrometry. LL-37 is susceptible to degradation by serum proteases; in vitro studies should account for serum concentration in media. Store lyophilized at -20°C; reconstituted solutions at -80°C in aliquots. The peptide can bind to plastic surfaces; use low-binding tubes and tips for quantitative work.

Key Research Context

Understanding the research context for LL-37: The Human Antimicrobial Peptide requires consideration of multiple factors including compound purity, experimental design, appropriate controls, and reproducibility standards. The scientific literature provides a foundation for evaluating the biological activity and potential applications of this compound category.

Research-grade compounds require rigorous quality verification before use in any experimental protocol. This includes confirming identity via mass spectrometry, verifying purity via HPLC chromatography (targeting ≥98% for definitive studies), and ensuring proper storage conditions have been maintained throughout the supply chain. A validated Certificate of Analysis from the supplier, ideally with third-party verification, is the minimum standard for quality assurance.

Experimental Design Considerations

Researchers should consider several practical factors when designing experiments with this compound. Dose-response curves should be established using at least three concentration points spanning the expected effective range. Vehicle controls must match the reconstitution buffer exactly. Time-course experiments help determine optimal treatment duration and peak effect windows. For in vivo studies, route of administration significantly affects bioavailability and tissue distribution patterns.

Proper reconstitution technique is essential for accurate dosing. Always inject diluent slowly along the vial wall rather than directly onto the lyophilized cake. Gentle swirling (never vortexing or shaking) prevents aggregation and denaturation. Use bacteriostatic water for multi-dose vials and sterile water for single-use preparations. Record the reconstitution date, concentration, and storage conditions for each vial.

Literature and Evidence Standards

When evaluating the research evidence for any peptide compound, consider the hierarchy of evidence: randomized controlled clinical trials provide the strongest evidence, followed by controlled preclinical studies in validated animal models, then in vitro cell culture studies, and finally computational or theoretical analyses. The number of independent research groups replicating findings, publication in peer-reviewed journals, and consistency of results across different experimental systems all contribute to the overall evidence quality assessment.

Researchers should also be aware of publication bias (positive results are more likely to be published than negative results) and the importance of proper statistical analysis in interpreting study outcomes. Effect sizes, confidence intervals, and appropriate statistical tests are as important as p-values in evaluating research significance. For a comprehensive understanding of peptide quality metrics, review our guide on what 98% purity means and how to interpret analytical data from qualified suppliers.

Methodological Framework

Rigorous research methodology is essential for generating reliable data with any research compound. The following framework outlines best practices for experimental design, quality control, and data interpretation that apply to studies involving this compound category.

Quality Control Protocol

Before initiating any experimental protocol, verify the compound identity and purity through independent analytical testing. The minimum verification standard includes reversed-phase HPLC analysis confirming ≥98% purity and mass spectrometry confirming the correct molecular weight within ±1 Da of the theoretical value. For compounds with disulfide bonds or metal coordination (such as copper peptides), additional analytical methods may be required to confirm proper folding or complexation. Document the lot number, vendor, CoA reference, and storage conditions for every compound used in research.

Dose-Response Characterization

Establishing a complete dose-response curve is fundamental to characterizing any bioactive compound. Use a minimum of five concentration points spanning at least two logarithmic orders of magnitude. Include both sub-threshold and supra-maximal concentrations to define the full response range. Calculate EC50 (half-maximal effective concentration) values using nonlinear regression with appropriate curve-fitting models. For in vivo studies, allometric scaling from published animal data provides initial dose estimates, but species-specific pharmacokinetic differences necessitate empirical dose optimization.

Controls and Replication

Every experiment requires appropriate controls: vehicle controls (matching the reconstitution buffer composition exactly), positive controls (a compound with known activity in the assay system), and negative controls (untreated or inactive analog). Biological replicates (independent experiments on different days with different cell passages or animal cohorts) are more informative than technical replicates (repeated measurements of the same sample). A minimum of three biological replicates is standard for publication-quality data. Statistical analysis should include measures of central tendency, variability (standard deviation or standard error), and appropriate hypothesis testing with correction for multiple comparisons where applicable.

Safety and Handling

All research compounds should be handled according to standard laboratory safety protocols. Wear appropriate personal protective equipment (gloves, lab coat, eye protection) when handling lyophilized powders and reconstituted solutions. Avoid inhalation of lyophilized powder during reconstitution. Dispose of unused compound and contaminated materials according to institutional biosafety and chemical waste guidelines. Research peptides are intended for laboratory research use only and are not approved for human therapeutic use unless specifically noted (such as FDA-approved compounds like Tesamorelin).

Proper storage extends compound viability and ensures consistent experimental results. Lyophilized compounds should be stored at -20°C with desiccant in sealed containers. After reconstitution with bacteriostatic water, store at 2-8°C and use within the validated stability window (typically 3-4 weeks). For long-term storage of reconstituted solutions, prepare single-use aliquots and freeze at -20°C to avoid repeated freeze-thaw cycles that accelerate degradation.

Frequently Asked Questions

What is LL-37?

LL-37 is the only human cathelicidin antimicrobial peptide. It kills bacteria by membrane disruption, recruits immune cells, promotes wound healing, and neutralizes endotoxin. Its expression is regulated by vitamin D.

Why is LL-37 important for immune defense?

As the sole human cathelicidin, LL-37 provides first-line innate defense against bacteria, fungi, and viruses. Its dual antimicrobial and immunomodulatory functions make it a bridge between innate detection and adaptive immune activation.

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. This article is intended for educational and informational purposes only. It does not constitute medical advice. Last updated: April 20, 2026.